Amyloid imaging also provides the opportunity for prospective ass

Amyloid imaging also provides the opportunity for prospective assessment of amyloid deposition in relation to changes in cognitive performance and regional brain volumes [47,52]. The ability to track pathology over time using both amyloid imaging and CSF measures of A?? [53] will enhance understanding of the temporal sequence of events in parallel and subsequent Palbociclib Phase 3 to amyloid deposition. Such studies may reveal whether there is some threshold beyond which memory impairment is evident and may identify factors that either render some individuals with substantial pathology resilient to disease or promote a delayed onset of clinical symptoms. Abbreviations A??: ??-amyloid; AD: Alzheimer’s disease; APOE: Apolipoprotein E; CN: cognitively normal; CSF: cerebrospinal fluid; MCI: mild cognitive impairment; MRI: magnetic resonance imaging; PET: positron emission tomography; PiB: [11C]Pittsburgh Compound-B.

Competing interests The authors declare that they have no competing interests. Note This article is part of a review series on Amyloid Imaging. Other articles in the series can be found online at http://alzres.com/series/amyloidimaging Acknowledgements This research was supported by the Intramural Research Program of the NIH, National Institute on Aging and N01-AG-3-2124.
The results of a randomized double-blind placebocontrolled trial with docosahexaenoic acid (DHA) supplementation in mild to moderate Alzheimer’s disease (AD) published by Quinn and colleagues in JAMA argues against overall efficacy of DHA in slowing progression.

However, certain caveats in the results caution against discarding DHA altogether, raising questions about oxidation, dosage, pharmacogenomics and stage of intervention. One potential misconception is that what works for prevention will slow progression Brefeldin_A in AD subjects. Preclinical studies with DHA supported the rationale for early stage intervention; and three epidemiological studies indicated DHA intake was associated with reduced risk in non-apolipoprotein E4 (ApoE4) carriers. Putative drugs are initially tested for impact on progression because prevention approaches are problematic. However, should a drug be discarded for prevention if it fails to modify progression? Consistent with epidemiology, DHA significantly benefited two measures of cognition in mild to moderate non-ApoE4 carriers. Although the results of this trial were overall negative, failing to modify other outcomes, this commentary discusses important questions raised by selleck kinase inhibitor them.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>